WM occupies approximately 42% by volume of the normal stroke-aged brain. Patients entered into typical trials of neuroprotection may have significant WM volumes involved in the ischemic process, thus providing a rationale for the development of neuroprotectants for this compartment.
No takes yet. Share an insight, caveat, or question.
Ho et al. (2005) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: